Skip to main content
SpringerLink
Log in

RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors

  • Original Paper
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Galectin-3 is expressed in a cell-type specific manner in human pituitary tumors and may have a role in pituitary tumor development. In this study, we hypothesized that Galectin-3 is regulated by RUNX proteins in pituitary tumors. Transcription factor prediction programs revealed several putative binding sites in the LGALS3 (Galectin-3 gene) promoter region. A human pituitary cell line HP75 was used as a model to study LGALS3 and RUNX interactions using Chromatin immunoprecipitation assay and electrophoresis mobility shift assay. Two binding sites for RUNX1 and one binding site for RUNX2 were identified in the LGALS3 promoter region. LGALS3 promoter was further cloned into a luciferase reporter, and the experiments showed that both RUNX1 and RUNX2 upregulated LGALS3. Knock-down of either RUNX1 or RUNX2 by siRNA resulted in a significant downregulation of Galectin-3 expression and decreased cell proliferation in the HP 75 cell line. Immunohistochemistry showed a close correlation between Galectin-3 expression and RUNX1/RUNX2 level in pituitary tumors. These results demonstrate a novel binding target for RUNX1 and RUNX2 proteins and suggest that Galectin-3 is regulated by RUNX1 and RUNX2 in human pituitary tumor cells by direct binding to the promoter region of LGALS3 and thus may contribute to pituitary tumor progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. M.P. Shekhar, P. Nangia-Makker, L. Tait, F. Miller, A. Raz, Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am. J. Pathol. 165, 1931–1941 (2004)

    CAS  PubMed  Google Scholar 

  2. H.C. Gong, Y. Honjo, P. Nangia-Makker, V. Hogan, N. Mazurak, R.S. Bresalier, A. Raz, The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res. 59, 6239–6245 (1999)

    CAS  PubMed  Google Scholar 

  3. F.T. Liu, G.A. Rabinovich, Galectins as modulators of tumour progression. Nat. Rev. Cancer 5, 29–41 (2005)

    Article  CAS  PubMed  Google Scholar 

  4. K. Yamaoka, K. Mishima, Y. Nagashima, A. Asai, Y. Sanai, T. Kirino, Expression of galectin-1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin-1 inhibits the growth of 9 glioma cells. J. Neurosci. Res. 59, 722–730 (2000)

    Article  CAS  PubMed  Google Scholar 

  5. Y. Takenaka, H. Inohara, T. Yoshii, K. Oshima, S. Nakahara, S. Akahani, Y. Honjo, Y. Yamamoto, A. Raz, T. Kubo, Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett. 195, 111–119 (2003)

    Article  CAS  PubMed  Google Scholar 

  6. R.C. Hughes, The galectin family of mammalian carbohydrate-binding molecules. Biochem. Soc. Trans. 25, 1194–1198 (1997)

    CAS  PubMed  Google Scholar 

  7. R.C. Hughes, Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim. Biophys. Acta 1473, 172–185 (1999)

    CAS  PubMed  Google Scholar 

  8. D. Riss, L. Jin, X. Qian, J. Bayliss, B.W. Scheithauer, W.F. Young Jr., S. Vidal, K. Kovacs, A. Raz, R.V. Lloyd, Differential expression of galectin-3 in pituitary tumors. Cancer Res. 63, 2251–2255 (2003)

    CAS  PubMed  Google Scholar 

  9. K.H. Ruebel, L. Jin, X. Qian, B.W. Scheithauer, K. Kovacs, N. Nakamura, H. Zhang, A. Raz, R.V. Lloyd, Effects of DNA methylation on galectin-3 expression in pituitary tumors. Cancer Res. 65, 1136–1140 (2005)

    Article  CAS  PubMed  Google Scholar 

  10. M. Stock, H. Schafer, S. Stricker, G. Gross, S. Mundlos, F. Otto, Expression of galectin-3 in skeletal tissues is controlled by Runx2. J. Biol. Chem. 278, 17360–17367 (2003)

    Article  CAS  PubMed  Google Scholar 

  11. A. Costessi, A. Pines, P. D’Andrea, M. Romanello, G. Damante, L. Cesaratto, F. Quadrifoglio, L. Moro, G. Tell, Extracellular nucleotides activate Runx2 in the osteoblast-like HOBIT cell line: a possible molecular link between mechanical stress and osteoblasts’ response. Bone 36, 418–432 (2005)

    Article  CAS  PubMed  Google Scholar 

  12. L. Jin, E. Kulig, X. Qian, B.W. Scheithauer, N.L. Eberhardt, R.V. Lloyd, A human pituitary adenoma cell line proliferates and maintains some differentiated functions following expression of SV40 large T antigen. Endocr. Pathol. 9, 169–184 (1998)

    Article  CAS  Google Scholar 

  13. K. Cartharius, K. Frech, K. Grote, B. Klocke, M. Haltmeier, A. Klingenhoff, M. Frisch, M. Bayerlein, T. Werner, MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21, 2933–2942 (2005)

    Article  CAS  PubMed  Google Scholar 

  14. T. Tsunoda, T. Takagi, Estimating transcription factor bindability on DNA. Bioinformatics 15, 622–630 (1999)

    Article  CAS  PubMed  Google Scholar 

  15. D. Levanon, V. Negreanu, Y. Bernstein, I. Bar-Am, L. Avivi, Y. Groner, AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics 23, 425–432 (1994)

    Article  CAS  PubMed  Google Scholar 

  16. Y. Kamachi, E. Ogawa, M. Asano, S. Ishida, Y. Murakami, M. Satake, Y. Ito, K. Shigesada, Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer. J. Virol. 64, 4808–4819 (1990)

    CAS  PubMed  Google Scholar 

  17. I.N. Melnikova, B.E. Crute, S. Wang, N.A. Speck, Sequence specificity of the core-binding factor. J. Virol. 67, 2408–2411 (1993)

    CAS  PubMed  Google Scholar 

  18. A.L. Zaiman, A.F. Lewis, B.E. Crute, N.A. Speck, J. Lenz, Transcriptional activity of core binding factor-alpha (AML1) and beta subunits on murine leukemia virus enhancer cores. J. Virol. 69, 2898–2906 (1995)

    CAS  PubMed  Google Scholar 

  19. G. Huang, K. Shigesada, K. Ito, H.J. Wee, T. Yokomizo, Y. Ito, Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J. 20, 723–733 (2001)

    Article  CAS  PubMed  Google Scholar 

  20. Y.W. Zhang, N. Yasui, K. Ito, G. Huang, M. Fujii, J. Hanai, H. Nogami, T. Ochi, K. Miyazono, Y. Ito, A RUNX2/PEBP2alpha A/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc. Natl. Acad. Sci. USA 97, 10549–10554 (2000)

    Article  CAS  PubMed  Google Scholar 

  21. J. Kononen, L. Bubendorf, A. Kallioniemi, M. Barlund, P. Schraml, S. Leighton, J. Torhorst, M.J. Mihatsch, G. Sauter, O.P. Kallioniemi, Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4, 844–847 (1998)

    Article  CAS  PubMed  Google Scholar 

  22. H. Miyoshi, M. Ohira, K. Shimizu, K. Mitani, H. Hirai, T. Imai, K. Yokoyama, E. Soeda, M. Ohki, Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. Nucleic Acids Res. 23, 2762–2769 (1995)

    Article  CAS  PubMed  Google Scholar 

  23. M.M. Kadrofske, K.P. Openo, J.L. Wang, The human LGALS3 (galectin-3) gene: determination of the gene structure and functional characterization of the promoter. Arch. Biochem. Biophys. 349, 7–20 (1998)

    Article  CAS  PubMed  Google Scholar 

  24. Y. Yamaguchi, M. Kurokawa, Y. Imai, K. Izutsu, T. Asai, M. Ichikawa, G. Yamamoto, E. Nitta, T. Yamagata, K. Sasaki, K. Mitani, S. Ogawa, S. Chiba, H. Hirai, AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. J. Biol. Chem. 279, 15630–15638 (2004)

    Article  CAS  PubMed  Google Scholar 

  25. Y.W. Zhang, S.C. Bae, G. Huang, Y.X. Fu, J. Lu, M.Y. Ahn, Y. Kanno, T. Kanno, Y. Ito, A novel transcript encoding an N-terminally truncated AML1/PEBP2 alphaB protein interferes with transactivation and blocks granulocytic differentiation of 32Dcl3 myeloid cells. Mol. Cell. Biol. 17, 4133–4145 (1997)

    CAS  PubMed  Google Scholar 

  26. T.K. Howcroft, J.D. Weissman, A. Gegonne, D.S. Singer, A T lymphocyte-specific transcription complex containing RUNX1 activates MHC class I expression. J. Immunol. 174, 2106–2115 (2005)

    CAS  PubMed  Google Scholar 

  27. T. Fukumori, N. Oka, Y. Takenaka, P. Nangia-Makker, E. Elsamman, T. Kasai, M. Shono, H.O. Kanayama, J. Ellerhorst, R. Lotan, A. Raz, Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res. 66, 3114–3119 (2006)

    Article  CAS  PubMed  Google Scholar 

  28. N. Oka, S. Nakahara, Y. Takenaka, T. Fukumori, V. Hogan, H.O. Kanayama, T. Yanagawa, A. Raz, Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Res. 65, 7546–7553 (2005)

    CAS  PubMed  Google Scholar 

  29. M. Volante, F. Bozzalla-Cassione, F. Orlandi, M. Papotti, Diagnostic role of galectin-3 in follicular thyroid tumors. Virchows Arch. 444, 309–312 (2004)

    Article  PubMed  Google Scholar 

  30. F. Roncaroli, B.W. Scheithauer, G. Cenacchi, E. Horvath, K. Kovacs, R.V. Lloyd, P. Abell-Aleff, M. Santi, A.J. Yates, ‘Spindle cell oncocytoma’ of the adenohypophysis: a tumor of folliculostellate cells? Am. J. Surg. Pathol. 26, 1048–1055 (2002)

    Article  PubMed  Google Scholar 

  31. P. Ducy, T. Schinke, G. Karsenty, The osteoblast: a sophisticated fibroblast under central surveillance. Science 289, 1501–1504 (2000)

    Article  CAS  PubMed  Google Scholar 

  32. B.E. Crute, A.F. Lewis, Z. Wu, J.H. Bushweller, N.A. Speck, Biochemical and biophysical properties of the core-binding factor alpha2 (AML1) DNA-binding domain. J. Biol. Chem. 271, 26251–26260 (1996)

    Article  CAS  PubMed  Google Scholar 

  33. T. Kanno, Y. Kanno, L.F. Chen, E. Ogawa, W.Y. Kim, Y. Ito, Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor alpha subunit revealed in the presence of the beta subunit. Mol. Cell. Biol. 18, 2444–2454 (1998)

    CAS  PubMed  Google Scholar 

  34. H. Kagoshima, K. Shigesada, M. Satake, Y. Ito, H. Miyoshi, M. Ohki, M. Pepling, P. Gergen, The Runt domain identifies a new family of heteromeric transcriptional regulators. Trends Genet. 9, 338–341 (1993)

    Article  CAS  PubMed  Google Scholar 

  35. Q. Wang, T. Stacy, M. Binder, M. Marin-Padilla, A.H. Sharpe, N.A. Speck, Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc. Natl. Acad. Sci. USA 93, 3444–3449 (1996)

    Article  CAS  PubMed  Google Scholar 

  36. T. Okuda, J. van Deursen, S.W. Hiebert, G. Grosveld, J.R. Downing, AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84, 321–330 (1996)

    Article  CAS  PubMed  Google Scholar 

  37. T. Komori, H. Yagi, S. Nomura, A. Yamaguchi, K. Sasaki, K. Deguchi, Y. Shimizu, R.T. Bronson, Y.H. Gao, M. Inada, M. Sato, R. Okamoto, Y. Kitamura, S. Yoshiki, T. Kishimoto, Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89, 755–764 (1997)

    Article  CAS  PubMed  Google Scholar 

  38. F. Otto, A.P. Thornell, T. Crompton, A. Denzel, K.C. Gilmour, I.R. Rosewell, G.W. Stamp, R.S. Beddington, S. Mundlos, B.R. Olsen, P.B. Selby, M.J. Owen, Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89, 765–771 (1997)

    Article  CAS  PubMed  Google Scholar 

  39. D. Levanon, D. Bettoun, C. Harris-Cerruti, E. Woolf, V. Negreanu, R. Eilam, Y. Bernstein, D. Goldenberg, C. Xiao, M. Fliegauf, E. Kremer, F. Otto, O. Brenner, A. Lev-Tov, Y. Groner, The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons. EMBO J. 21, 3454–3463 (2002)

    Article  CAS  PubMed  Google Scholar 

  40. K. Inoue, S. Ozaki, T. Shiga, K. Ito, T. Masuda, N. Okado, T. Iseda, S. Kawaguchi, M. Ogawa, S.C. Bae, N. Yamashita, S. Itohara, N. Kudo, Y. Ito, Runx3 controls the axonal projection of proprioceptive dorsal root ganglion neurons. Nat. Neurosci. 5, 946–954 (2002)

    Article  CAS  PubMed  Google Scholar 

  41. H.M. Robinson, Z.J. Broadfield, K.L. Cheung, L. Harewood, R.L. Harris, G.R. Jalali, M. Martineau, A.V. Moorman, K.E. Taylor, S. Richards, C. Mitchell, C.J. Harrison, Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia 17, 2249–2250 (2003)

    Article  CAS  PubMed  Google Scholar 

  42. G.L. Barnes, K.E. Hebert, M. Kamal, A. Javed, T.A. Einhorn, J.B. Lian, G.S. Stein, L.C. Gerstenfeld, Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res. 64, 4506–4513 (2004)

    Article  CAS  PubMed  Google Scholar 

  43. A. Kilbey, K. Blyth, S. Wotton, A. Terry, A. Jenkins, M. Bell, L. Hanlon, E.R. Cameron, J.C. Neil, Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Res. 67, 11263–11271 (2007)

    Article  CAS  PubMed  Google Scholar 

  44. V. Vladimirova, A. Waha, K. Luckerath, P. Pesheva, R. Probstmeier, Runx2 is expressed in human glioma cells and mediates the expression of galectin-3. J. Neurosci. Res. 86, 2450–2461 (2008)

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This research was supported in part by NIH Grant CA90249 and a Grant from the Jarislowsky Foundation to RVL) and NIH Grant R37CA46120-19 (to AR).

Author information

Authors and Affiliations

  1. Department of Pathology, Mayo Clinic College of Medicine, 200, 1 Street SW, Rochester, MN, 55905, USA

    He-Yu Zhang, Long Jin, Gail A. Stilling, Katharina H. Ruebel, Kendra Coonse, Yoshinori Tanizaki & Ricardo V. Lloyd

  2. Tumor Progression and Metastasis Program, Karmanos Cancer Institute, Wayne State University, Detroit, MI, 48201, USA

    Avraham Raz

Authors
  1. He-Yu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Long Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gail A. Stilling
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katharina H. Ruebel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kendra Coonse
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshinori Tanizaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Avraham Raz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ricardo V. Lloyd
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ricardo V. Lloyd.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, HY., Jin, L., Stilling, G.A. et al. RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors. Endocr 35, 101–111 (2009). https://doi.org/10.1007/s12020-008-9129-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-008-9129-z

Keywords

Search

Navigation